$TFF Pharmaceuticals (TFFP.US)$ NEWS TFF Pharmaceuticals Pro...
NEWS
TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection
TFF Pharmaceuticals announced an update on its Phase 2 trial of Tacrolimus Inhalation Powder (TFF TAC) for preventing lung transplant rejection. The trial has accelerated patient enrollment with 10 patients currently enrolled. All 6 patients who completed the 12-week treatment have opted to continue to the safety extension phase. One patient has been on treatment for over a year, and three others for more than six months.
The initial pharmacokinetic (PK) data shows reduced systemic variability with TFF TAC, potentially lowering risks of acute rejection and systemic toxicities. Positive feedback includes reduced headaches and improved wellness. A more detailed clinical update is expected later in the year.
The initial pharmacokinetic (PK) data shows reduced systemic variability with TFF TAC, potentially lowering risks of acute rejection and systemic toxicities. Positive feedback includes reduced headaches and improved wellness. A more detailed clinical update is expected later in the year.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
950Followers
63Following
6415Visitors
Follow